Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain.

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

The symptoms of Parkinson’s disease could be reversed through injections of nanoparticles into the brain, which is a much ...

Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction. Its pathological hallmark is the abnormal aggregation of α-synuclein ...

During the pathogenesis of Parkinson’s disease (PD), α-synuclein pathology may originate in peripheral organs and spread to the CNS. Using human tissue samples and multiple approaches in mouse ...

Increased α-synuclein expression is implicated both in hereditary and sporadic Parkinson's disease. Proteomic analysis has identified a series of post-translational modifications in inclusions.

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's ...